Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + sintilimab + oxaliplatin + 5-fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy regimen is being investigated as a first-line treatment for metastatic intrahepatic cholangiocarcinoma (ICC) in clinical trials led by Sun Yat-sen University. The regimen integrates the anti-angiogenic tyrosine kinase inhibitor apatinib, the PD-1-targeting monoclonal antibody sintilimab, and the FOLFOX chemotherapy backbone (comprising oxaliplatin, 5-fluorouracil, and leucovorin). Apatinib selectively inhibits VEGFR-2 to disrupt tumor blood supply, while sintilimab restores T-cell activity against tumor cells by blocking the PD-1/PD-L1 checkpoint. The addition of FOLFOX provides direct cytotoxic effects through DNA alkylation and thymidylate synthase inhibition, potentially enhancing the immunogenicity of the tumor and leading to synergistic anti-tumor activity in advanced biliary tract cancers.
- Other names
- apatinib-Sun Yat-sen University-intrahepatic cholangiocarcinomaapatinib + sintilimab + FOLFOXFOLFOX + apatinib + sintilimabFOLFOX-AS
02
Targets
TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on apatinib + sintilimab + oxaliplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + sintilimab + oxaliplatin + 5-fluorouracil + leucovorin.